병원약사회지 (Journal of Korean Society of Health-System Pharmacists)

  • 제35권4호
  • /
  • Pages.400-408
  • /
  • 2018
  • /
  • 1226-640X(pISSN)
  • /
  • 2466-2143(eISSN)
한국병원약사회 (The Korean Society of Health-System Pharmacists)
권호 표지
DOI QR코드

DOI QR Code

손위형제 또는 자매가 있는 소아에서 Palivizumab 투여 여부에 따른 임상적 효과 분석

Analysis of Clinical Effects of Palivizumab for Children with Older Siblings

  • 김진여 (연세대학교의료원 세브란스병원 약무국) ;
  • 박지은 (연세대학교의료원 세브란스병원 약무국) ;
  • 정민재 (연세대학교의료원 세브란스병원 약무국) ;
  • 김재송 (연세대학교의료원 세브란스병원 약무국) ;
  • 김수현 (연세대학교의료원 세브란스병원 약무국) ;
  • 손은선 (연세대학교의료원 세브란스병원 약무국)
  • Kim, Jin Yeo (Department of Pharmacy, Severance Hospital, Yon-sei University Health System) ;
  • Park, Ji Eun (Department of Pharmacy, Severance Hospital, Yon-sei University Health System) ;
  • Jung, Min Jae (Department of Pharmacy, Severance Hospital, Yon-sei University Health System) ;
  • Kim, Jae Song (Department of Pharmacy, Severance Hospital, Yon-sei University Health System) ;
  • Kim, Soo Hyun (Department of Pharmacy, Severance Hospital, Yon-sei University Health System) ;
  • Son, Eun Sun (Department of Pharmacy, Severance Hospital, Yon-sei University Health System)
  • 투고 : 2018.02.08
  • 심사 : 2018.09.14
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016. Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration. Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p 0.05). Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.

키워드

참고문헌

  1. Park HW, Lee BS, Kim AR et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J. 2012;31(8):e99-e104. https://doi.org/10.1097/INF.0b013e318257f619
  2. Lee YI, Peng CC, Chiu NC et al. Risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants; J Microbiol Immunol Infect. 2016;49(5):737-742. https://doi.org/10.1016/j.jmii.2014.08.020
  3. Pangesti KNA, Abd El Ghany M, Walsh MG et al. Molecular epidemiology of respiratory syncytial virus; Rev Med Virol. 2018;28(2);doi:10.1002/rmv.1968.
  4. Thorburn K, Eisenhut M, Riordan A et al. Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children-A ten year perspective; Minerva Anestesiol. 2012;78(7):782-789.
  5. Rose EB, Wheatley A, Langley G et al. Respiratory Syncytial Virus Seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018;67(2):71-76. https://doi.org/10.15585/mmwr.mm6702a4
  6. Jacoby P, Glass K, Moore HC et al. Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study; Epidemiol Infect. 2017;145(2):266-271. https://doi.org/10.1017/S0950268816002545
  7. Health insurance review & assurement service: insurance approval standard page [Internet]: Palivizumab inj; 2016 October 1 [updated 2016 October 1; cited 2016 October1]. Available from http://www.hira.or.kr/rd/insuadtcrtr/InsuAdtCrtrList.do?pgmid=HIRAA030069000000.
  8. Mochizuki H, Kusuda S, Okada K et al. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing: 6 Year Follow up Study. Am J Respir Crit Care Med. 2017;196(1):29-38. https://doi.org/10.1164/rccm.201609-1812OC
  9. Kurz H, Herbich K, Janata O et al. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. J Hosp Infect 2008;70(3):246-252. https://doi.org/10.1016/j.jhin.2008.07.013
  10. Castillo LM, Bugarin G, Arias JC et al. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. J Pediatr (Rio J). 2017;93(5):467-474. https://doi.org/10.1016/j.jped.2016.11.006
  11. Chang SG, Park MS, Yu JE. Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009. J Korean Med Sci. 2010;25(2):251-256. https://doi.org/10.3346/jkms.2010.25.2.251
  12. Sommer C, Resch B, Simoes EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011;5:144-154. https://doi.org/10.2174/1874285801105010144
  13. Chan P, Li A, Paes B et al. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2015;34(12):e290-297. https://doi.org/10.1097/INF.0000000000000922
  14. Mauskopf J, Margulis AV, Samuel M et al. Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review. Pediatr Infect Dis J. 2016;35(7):e229-238. https://doi.org/10.1097/INF.0000000000001163
  15. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee, Pediatrics. 2014;134(2):e620-638. https://doi.org/10.1542/peds.2014-1666
  16. Alan S, Erdeve O, Cakir U et al. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study. J Matern Fetal Neonatal Med. 2016;29(13):2186-2193. https://doi.org/10.3109/14767058.2015.1079614
  17. Reeves RM, Hardelid P, Gilbert R et al. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012. Influenza Other Respir Viruses. 2017;11(2):122-129. https://doi.org/10.1111/irv.12443
  18. Hernandez-Gago Y, Lombardero-Pin M, Ortega de la Cruz C. Cost effectiveness of a protocol using palivizumab in preterm infants. Farm Hosp. 2017;41(2):169-186.